T-cell prolymphocytic leukemia

This early-phase trial tests two drugs, ruxolitinib and duvelisib, together in people whose T- or NK-cell lymphoma has come back or stopped responding to treatment. The main goal is to find the safest dose of duvelisib when combined with a fixed dose of ruxolitinib. About 70 part…

This study tests a new treatment using immune cells (NK cells) from donated cord blood that are engineered to target a protein called CD5 found on certain cancer cells. The treatment is given after chemotherapy to prepare the body, and the goal is to see if it is safe and effecti…

This early-phase trial tests whether combining three drugs—ruxolitinib, cladribine, and venetoclax—can control T-cell prolymphocytic leukemia (T-PLL) that has returned or not responded to prior treatment. The study will enroll 36 adults and primarily monitor safety and side effec…

This trial investigates whether combining two FDA-approved drugs, duvelisib and venetoclax, can safely and effectively treat peripheral T-cell lymphoma that has returned or stopped responding to prior therapies. The study enrolls adults who have tried at least two previous treatm…

This early-stage study tests a new oral drug, LP-118, in up to 100 adults with blood cancers like lymphoma, leukemia, or myeloma that returned or didn't respond to prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the disease.…

This phase II trial is testing whether the drug ruxolitinib, taken as a daily pill after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD). The study will enroll 44 adults with various T-cell lymphoma…

This study is for adults with two types of blood cancer—T-PLL or NHL—that have not responded to or have returned after previous treatments. Researchers are testing a new drug called APG-115, either alone or combined with another drug APG-2575, to find the safest dose and see if i…

This study gathers information from 50 people with T-cell prolymphocytic leukemia (T-PLL), a rare and aggressive blood cancer. Researchers will look at patients' medical records, lab results, and genetic data to better understand the disease and how it responds to current treatme…

This study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…

This study is a registry that will follow up to 8,000 people with chronic lymphocytic leukemia (CLL) and related blood cancers over many years. It does not test a new treatment but instead collects information on how patients are doing over time, including survival. The goal is t…